Abous Us

Corporate profile

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain.

“Although few people die of pain, many still die in pain, while even more live in pain. We will leave no stone unturned to help these patients.”

Gabriel Baertschi

Chief Executive Officer, Grünenthal

As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to people living with pain worldwide. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. We are a fully integrated pharmaceutical company that offers support along the entire value chain – from drug development through to commercialisation.

Strong and capable team

employees worldwide

Solid revenue base

billion euros in 2023

Commercial presence in

countries across Europe, Latin America, and the US

Products sold in around


International network

R&D sites – one R&D Unit in Aachen (Germany) and an Innovation Hub in Boston, (USA)

Production capacities

manufacturing sites in Europe and Latin America

Contract Manufacturing GRT PRO

Global capabilities

Although firmly rooted in Germany, today we are very much a growing global business: since spreading our wings beyond Germany in the 1960s, we have continued to grow steadily and expand our market presence and product portfolio. We collaborate with commercial partners and multiple stakeholders from the pain management field and beyond in order to make our medicines available to patients.

... Explore our global presence and sites


To move closer to our vision of a world free of pain, we are currently pursuing a range of programs across different modalities, targets, and mechanisms of action. Here are some selected highlights from our development pipeline: RTX (resiniferatoxin), MPC-06-ID, Glucocorticoid Receptor Modulator (GRM), Nociceptin/Orphanin FQ receptor Peptide agonist (NOP).

... Explore Grünenthal's development pipeline